Kinnate Biopharma Valuation
Is KNTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KNTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KNTE?
Key metric: As KNTE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is KNTE's PB Ratio? | |
|---|---|
| PB Ratio | 0.8x |
| Book | US$159.33m |
| Market Cap | US$125.15m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does KNTE's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.6x | ||
PYXS Pyxis Oncology | 0.7x | -24.0% | US$105.3m |
MCRB Seres Therapeutics | 6.5x | -17.2% | US$149.7m |
DBTX Decibel Therapeutics | 2.3x | n/a | US$124.3m |
RPTX Repare Therapeutics | 0.8x | -16.7% | US$133.9m |
KNTE Kinnate Biopharma | 0.8x | 14.6% | US$125.1m |
Price-To-Book vs Peers: KNTE is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.4x).
Price to Book Ratio vs Industry
How does KNTE's PB Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: KNTE is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is KNTE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate KNTE's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Nov ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Oct ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Sep ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Aug ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Jul ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Jun ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| May ’25 | n/a | US$2.30 0% | 12.9% | US$2.59 | US$2.00 | n/a | 2 |
| Apr ’25 | US$2.66 | US$4.53 +70.3% | 70.0% | US$9.00 | US$2.00 | n/a | 3 |
| Mar ’25 | US$2.59 | US$3.98 +53.8% | 72.9% | US$9.00 | US$2.00 | n/a | 4 |
| Feb ’25 | US$2.34 | US$3.75 +60.6% | 67.9% | US$9.00 | US$1.50 | n/a | 6 |
| Jan ’25 | US$2.37 | US$3.75 +58.2% | 67.9% | US$9.00 | US$1.50 | n/a | 6 |
| Dec ’24 | US$2.25 | US$3.75 +66.7% | 67.9% | US$9.00 | US$1.50 | n/a | 6 |
| Nov ’24 | US$1.12 | US$3.75 +234.8% | 67.9% | US$9.00 | US$1.50 | n/a | 6 |
| Oct ’24 | US$1.40 | US$3.75 +167.9% | 67.9% | US$9.00 | US$1.50 | n/a | 6 |
| Sep ’24 | US$2.35 | US$23.30 +891.5% | 45.9% | US$44.00 | US$5.40 | n/a | 8 |
| Aug ’24 | US$2.69 | US$23.93 +789.4% | 47.1% | US$44.00 | US$5.40 | n/a | 8 |
| Jul ’24 | US$3.03 | US$23.93 +689.6% | 47.1% | US$44.00 | US$5.40 | n/a | 8 |
| Jun ’24 | US$4.30 | US$23.93 +456.4% | 47.1% | US$44.00 | US$5.40 | n/a | 8 |
| May ’24 | US$2.65 | US$24.00 +805.7% | 47.3% | US$44.00 | US$5.00 | n/a | 8 |
| Apr ’24 | US$6.25 | US$29.75 +376.0% | 32.8% | US$44.00 | US$8.00 | US$2.66 | 8 |
| Mar ’24 | US$5.21 | US$30.75 +490.2% | 29.0% | US$45.00 | US$11.00 | US$2.59 | 8 |
| Feb ’24 | US$7.90 | US$31.88 +303.5% | 31.5% | US$46.00 | US$11.00 | US$2.34 | 8 |
| Jan ’24 | US$6.10 | US$31.88 +422.5% | 31.5% | US$46.00 | US$11.00 | US$2.37 | 8 |
| Dec ’23 | US$7.75 | US$31.88 +311.3% | 31.5% | US$46.00 | US$11.00 | US$2.25 | 8 |
| Nov ’23 | US$8.60 | US$35.25 +309.9% | 16.1% | US$46.00 | US$29.00 | US$1.12 | 8 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Collegium Pharmaceutical
US$1.0b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.71
7D
2.4%
1Y
20.0%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$59.39
7D
7.8%
1Y
20.6%
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.57
7D
-2.7%
1Y
71.0%